Page last updated: 2024-12-06

lodoxamide ethyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LodoXamide ethyl is a mast cell stabilizer that inhibits the release of histamine and other inflammatory mediators. It has been used clinically to treat allergic conjunctivitis. LodoXamide ethyl is a synthetic compound with a complex structure that is typically synthesized through a multi-step process involving several chemical reactions. The synthesis of LodoXamide ethyl involves starting with readily available starting materials and then carrying out a series of reactions to build up the desired molecule. LodoXamide ethyl exerts its effects by binding to a specific receptor on mast cells, preventing the release of histamine and other inflammatory mediators. LodoXamide ethyl has been shown to be effective in reducing symptoms of allergic conjunctivitis, such as itching, redness, and swelling. It is available as eye drops and is generally well-tolerated. LodoXamide ethyl is an important drug for the treatment of allergic conjunctivitis. It is a safe and effective alternative to other antihistamines and mast cell stabilizers. LodoXamide ethyl is studied to better understand its mechanism of action, identify potential side effects, and develop new and improved treatments for allergic conjunctivitis.'

lodoxamide ethyl: inhibits anaphylactic reactions; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID40915
CHEMBL ID2107161
SCHEMBL ID667976
MeSH IDM0076962

Synonyms (26)

Synonym
lodoxamide ethyl
u-42718
53882-13-6
D04760
lodoxamide ethyl (usan)
lodoxamide ethyl [usan]
acetic acid, 2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxo-, diethyl ester
diethyl n,n'-(2-chloro-5-cyano-m-phenylene)dioxamate
u42718
lodoxamide diethyl
u-42,718
u 42,718
2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxoacetic acid), diethyl ester
ethyl 2-[2-chloro-5-cyano-3-[(2-ethoxy-2-oxoacetyl)amino]anilino]-2-oxoacetate
tqy1b8145b ,
unii-tqy1b8145b
lodoxamide diethyl ester [mi]
acetic acid, 2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)-, bis 2-oxo-, diethyl ester
lodoxamide ethyl [mart.]
CHEMBL2107161
lodoxamide diethyl ester
SCHEMBL667976
DTXSID90202137
ethyl (2-chloro-5-cyano-3-{[ethoxy(oxo)acetyl]amino}anilino)(oxo)acetate
ethyl2-[2-chloro-5-cyano-3-[(2-ethoxy-2-oxoacetyl)amino]anilino]-2-oxoacetate
Q27290175

Research Excerpts

Overview

Lodoxamide ethyl is a new cromolyn-like drug. It prevents antigen-induced mediator release from mast cells and antigen- induced bronchoconstriction in sensitive animals and man.

ExcerptReferenceRelevance
"Lodoxamide ethyl is a new cromolyn-like drug which prevents antigen-induced mediator release from mast cells and antigen-induced bronchoconstriction in sensitive animals and man. "( Effect of iodoxamide ethyl on allergy skin tests.
Frigas, E; Reed, CE, 1980
)
1.7

Toxicity

ExcerptReferenceRelevance
" Both drugs were safe for topical ophthalmic use when used four times daily for up to 28 days."( Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis.
Caldwell, DR; Drake, MM; Hartwich-Young, R; Meyer, SM; Verin, P, 1992
)
0.28
" No side effect related to the use of the drug has been noted."( [Evaluation of efficacy and safety of sterile solution of lodoxamide in patients with ocular allergy].
Nicoară, S, 2001
)
0.31
"Topical lodoxamide eye drops, when used for treatment of VKC, are effective with fewer adverse effects."( Safety and efficacy of lodoxamide in vernal keratoconjunctivitis.
Alam, R; Das, D; Gul, A; Khan, M, 2011
)
0.37
" This medication has proved to be safe and well tolerated."( Efficacy and safety of 0.1% lodoxamide for the long-term treatment of superior limbic keratoconjunctivitis.
Gonzalez-Gonzalez, JM; Macias-Rodriguez, Y; Rodriguez-Garcia, A, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" The neutrophil dose-response curve for increase in XO paralleled closely the curve for neutrophil-mediated RPAEC cytotoxicity."( Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils.
Gannon, DE; Phan, SH; Ryan, US; Varani, J; Ward, PA, 1989
)
0.28
" Attempts were made to decrease the theophylline dosage by sequentially reducing the dose each week to one-half, one-quarter, and discontinuation."( Lack of significant arrhythmogenicity from chronic theophylline and beta-2-adrenergic combination therapy in asthmatic subjects.
Kelly, HW; Menendez, R; Voyles, W, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1134837Antiallergic activity in anti-egg albumin homocytotropic antibody-sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis reaction at 50 mg/kg, po administered 20 mins prior to antigen egg albumin challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
N,N'-(Phenylene)dioxamic acids and their esters as antiallergy agents.
AID1134843Antiallergic activity in anti-egg albumin homocytotropic antibody-sensitized Sprague-Dawley rat assessed as time of peak action for inhibition of passive cutaneous anaphylaxis reaction at 50 mg/kg, po administered prior to antigen egg albumin challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
N,N'-(Phenylene)dioxamic acids and their esters as antiallergy agents.
AID1134846Antiallergic activity in po dosed anti-egg albumin homocytotropic antibody-sensitized Sprague-Dawley rat assessed as lowest concentration required for >20% inhibition of passive cutaneous anaphylaxis reaction administered prior to antigen egg albumin chal1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
N,N'-(Phenylene)dioxamic acids and their esters as antiallergy agents.
AID1134836Antiallergic activity in anti-egg albumin homocytotropic antibody-sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis reaction at 50 mg/kg, po administered 5 mins prior to antigen egg albumin challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
N,N'-(Phenylene)dioxamic acids and their esters as antiallergy agents.
AID1134838Antiallergic activity in anti-egg albumin homocytotropic antibody-sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis reaction at 50 mg/kg, po administered 60 mins prior to antigen egg albumin challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
N,N'-(Phenylene)dioxamic acids and their esters as antiallergy agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (20.90)18.7374
1990's33 (49.25)18.2507
2000's14 (20.90)29.6817
2010's6 (8.96)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.99 (24.57)
Research Supply Index4.60 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials26 (36.11%)5.53%
Reviews4 (5.56%)6.00%
Case Studies1 (1.39%)4.05%
Observational0 (0.00%)0.25%
Other41 (56.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]